

LIST OF TABLES

| Table No. | Title | Page No. |
|------------------|---|-----------------|
| 1.1 | Variable factors affecting the permeability of drugs through the nasal mucosa | 2 |
| 1.2 | Advantages and limitations of nasal drug delivery system | 3 |
| 1.3 | Structural features of different sections of nasal cavity and their relative impact on permeability | 4 |
| 1.4 | Barriers to drug crossing the nasal membrane | 6 |
| 2.1 | Tapentadol base is characterized by various physicochemical properties | 26 |
| 2.2 | Saturated solubility of Tapentadol base | 28 |
| 2.3 | Pharmacokinetics of the present IR formulation (7, 8) | 30 |
| 3.1 | Calibration data of the developed method of Tapentadol | 34 |
| 3.2 | Accuracy and precision data for the developed method | 36 |
| 3.3 | Results of intermediate precision study | 37 |
| 3.4 | Bio-analytical method for estimation of Tapentadol in rabbit plasma | 38 |
| 3.5 | Instrumentation, apparatus, and consumables | 38 |
| 3.6 | Internal standard | 39 |
| 3.7 | Reference standards / Working standards | 40 |
| 3.8 | Within-batch or intra-batch accuracy | 42 |
| 3.9 | Between-batch or inter-batch accuracy | 43 |
| 3.10 | Within-batch or intra-batch precision | 43 |
| 3.11 | Between-batch or inter-batch precision | 44 |
| 3.12 | Recovery of Tapentadol | 44 |
| 3.13 | Dilution Integrity | 45 |
| 3.14 | Stock solution stability of Tapentadol and Tramadol (6 days at 2-8°C) | 46 |
| 3.15 | Stock solution stability of Tapentadol and Tramadol (11 hours at room temperature) | 47 |
| 3.16 | Spiking stock solution stability of Tapentadol and Tramadol (6 days at 2-8°C) | 48 |
| 3.17 | Bench top stability of Tapentadol at room temperature for 9 hours. | 49 |
| 3.18 | Freeze and thaw stability of Tapentadol | 50 |

| Table No. | Title | Page No. |
|------------------|--|-----------------|
| 3.19 | Process stability of Tapentadol | 50 |
| 3.20 | Rejected validation parameters | 50 |
| 4.1 | Solution state stability for Tapentadol Hydrochloride | 74 |
| 4.2 | Tapentadol and excipients compatibility study at Controlled room temperature ($25\pm 2^{\circ}\text{C}$ / $60\pm 5\% \text{RH}$) | 75 |
| 4.3 | Tapentadol and excipients compatibility study at controlled room temperature ($40\pm 2^{\circ}\text{C}$ / $75\pm 5\% \text{RH}$) | 75 |
| 5.1 | Optimized lyophilization cycle for Tapentadol SLN | 81 |
| 5.2 | Composition and characterization of TAP loaded SLN prepared by hot homogenization method | 85 |
| 5.3 | Effect cryoprotectant on the characteristics of TAP SLN | 89 |
| 5.4 | Optimized Lyophilization Cycle | 90 |
| 5.5 | Stability study results of optimized Tapentadol loaded SLN formulations in three different condition | 94 |
| 6.1 | Total protein value for method standardization. | 100 |
| 6.2 | Total LDH value for method standardization. | 102 |
| 6.3 | Mean plasma concentration versus time profile of oral versus intranasal Tapentadol base and SLN suspended particles | 107 |
| 6.4 | Summary of pharmacokinetic parameters Oral versus Intranasal Tapentadol; Base versus Solid Lipid Nanoparticles | 108 |
| 6.5 | Extrapolated brain values from Tapentadol plasma concentration | 111 |
| 6.6 | Extrapolated brain PK parameters | 113 |

LIST OF FIGURES

| Figure No | Title | Page No. |
|-----------|---|----------|
| 1.1 | Schematic of a sagittal section of human nasal cavity showing the nasal vestibule respiratory region: inferior turbinate, middle turbinate and the superior turbinate, the olfactory region and nasopharynx | 5 |
| 1.2 | Cell types of the nasal epithelium showing ciliated cell, non-ciliated cell, goblet cells, gel mucus layer, sol layer, basal cell and basement membrane | 5 |
| 1.3 | Disappearance from the absorption site in the nasal cavity | 6 |
| 1.4 | Diagram of disappearance from the absorption site in the nasal cavity assuming subsequent absorption from the GI tract | 7 |
| 1.5 | Different pathways for reaching the brain after intranasal administration | 9 |
| 1.6 | Classification of endocytosis based on endocytosis proteins that are involved in the initial entry of particles and solutes | 11 |
| 1.7 | Schematic procedure of hot and cold homogenization techniques for SLN | 14 |
| 2.1 | DSC thermogram of Tapentadol base | 27 |
| 2.2 | Neuronal and receptor pathway for the Tapentadol | 28 |
| 3.1 | Calibration curve of Tapentadol in phosphate buffer | 35 |
| 4.1 | IR spectrum of Tapentadol base | 67 |
| 4.2 | DSC thermogram of Tapentadol base | 67 |
| 4.3 | Initial Photograph of Tapentadol base at 20X | 68 |
| 4.4 | Raman spectra of Tapentadol base | 69 |
| 4.5 | Raman spectra of Glyceryl behenate | 69 |
| 4.6 | Raman spectra of Sucrose | 70 |

| Figure No | Title | Page No. |
|-----------|--|----------|
| 4.7 | Raman spectra of Hypromellose (HPMC), 6 cps | 70 |
| 4.8 | Raman spectra of Gellan gum | 71 |
| 4.9 | Raman spectra of Drug and SLN particle powder | 71 |
| 4.10 | Tapentadol base and glyceryl behenate overlay Raman spectrograph after 4 th week 40 ± 2°C/75 ± 5% RH | 72 |
| 4.11 | Tapentadol base and Sucrose overlay Raman spectrograph after 4 th week 40 ± 2°C/75 ± 5% RH | 72 |
| 4.12 | Tapentadol base and Polysorbate 80 overlay Raman spectrograph after 4 th week 40 ± 2°C/75 ± 5% RH | 73 |
| 4.13 | Tapentadol base and Hypromellose (6cps) overlay Raman spectrograph after 4 th week 40 ± 2°C/75 ± 5% RH | 73 |
| 4.14 | Tapentadol base and Gellan gum overlay Raman spectrograph after 4 th week 40 ± 2°C/75 ± 5% RH | 73 |
| 5.1 | Schematic representation of Hot homogenization techniques for preparation of TAP loaded SLN | 80 |
| 5.2 | Microscopic View at 50X (BeforeLyo) | 86 |
| 5.3 | Microscopic View at 50X (After Lyo) | 86 |
| 5.4 | Effect of amount of type and concentration of surfactant on prepared TAP SLN particle size | 87 |
| 5.5 | Effect of amount of type and concentration of surfactant on prepared TAP SLN Encapsulation efficiency and Loading efficiency | 88 |
| 5.6 | Effect cryoprotectant on the characteristics of TAP SLN | 89 |
| 5.7 | In-vitro cumulative percent release profile of SLN along with physical dispersion | 92 |

| Figure No | Title | Page No. |
|------------------|--|-----------------|
| 6.1 | Total protein value in comparison to normal saline and 1%, 4% BKC administration | 101 |
| 6.2 | Total LDH value in comparison to normal saline and 1%, 4% BKC administration | 103 |
| 6.3 | Plasma Concentration versus time profile oral route versus two intranasal formulations | 107 |
| 6.4 | Repeat Dose Pharmacokinetics Simulation with every 4 hrs. administration | 110 |
| 6.5 | Repeat Dose Pharmacokinetics Simulation with every 6 hrs. administration | 110 |
| 6.6 | Log Transformed Brain concentration of Tapentadol SLN (Predicted Vs Observed) | 111 |
| 6.7 | Log Transformed Brain concentration of Tapentadol base (Predicted Vs Observed) | 112 |

LIST OF ABBREVIATIONS AND SYMBOLS

| Abbreviation | Description |
|---------------------|-----------------------------------|
| µl | Microlitre |
| µm | Micrometer |
| AFM | Atomic force microscopy |
| API | Active Pharmaceutical Ingredient |
| AUC | Area under Curve |
| BBB | Blood Brain Barrier |
| CDC | Cell Division Code |
| CNS | Central nervous system |
| CR | Controlled Release |
| CSF | Cerebro Spinal Fluid |
| CV | Coefficient of variation |
| DL | Detection limit |
| DSC | Differential Scanning Calorimetry |
| e.g. | Example |
| ER | Extended Release |
| ESR | Erythrocyte Sedimentation Rate |
| FDA | Food Drug Administration |
| FFF | Field Flow Fractionation |
| FTIR | Fourier-Transformed Infra Red |
| GI | Gastrointestinal |
| H ₁ | Histamine-1 |

| Abbreviation | Description |
|---------------------|---|
| HCl | Hydrochloric Acid |
| HPH | High-Pressure Homogenizer |
| HQC | Highest quantification concentration |
| ICH | International Conference Harmonization |
| IN | Intranasal |
| IgA | Immunoglobulin A |
| IR | Immediate Release |
| IUPAC | International Unit |
| K_{abs} | Absorption rate constant |
| KCl | Potassium chloride |
| kDa | Kilo-dalton |
| K_{deg} | Degree constant |
| K_m | Mass correction factor |
| LC-MS | Liquid chromatography-Mass spectrometry |
| LD | Laser Diffraction |
| LLOQ | Lower limit of quantification |
| LQC | Lower quantification concentration |
| MQC | Medium quantification concentration |
| NMR | Nuclear magnetic Resonance |
| NSAID | Non-Steroidal Anti-Inflammatory Drug |

| Abbreviation | Description |
|---------------------|-----------------------------------|
| NZ | New Zealand |
| PCS | Photon correlation spectroscopy |
| PDI | Polydispersity index |
| PK | Pharmacokinetic |
| pK _a | Dissociation constant |
| QL | Quantitation Limit |
| RT | Retention Time |
| SLDDS | Solid Lipid Drug Delivery Systems |
| SLN | Solid Lipid Nano particles |
| USA | United States of America |
| UV | Ultra Violet |
| V _{max} | Maximum Velocity |
| WFI | Water for injection |
| Δmax | Delta Max |